InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Takes Additional Step toward Clinical Trials for INM-750

Moving toward offering the very first therapy for treating epidermolysis bullosa (EB), InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) recently announced it has signed an agreement with Pharmaseed Ltd. ( to develop a final formulation for INM-750, InMed’s lead compound, which is being developed as a therapy for EB and for other potential dermatological and wound-healing applications.

EB is a group of inherited connective tissue diseases sharing a common manifestation of very fragile skin that is prone to easily blistering or tearing. An orphan disease that currently has no approved treatments and has significant unmet medical need, EB results from a defect in anchoring between the dermis and the epidermis and is most commonly caused by the absence of specific keratins in the skin. In addition to its effects on the skin, EB can also affect bodily systems and internal organs.

InMed’s INM-750 is a proprietary topical product candidate that includes multiple cannabinoids as its active ingredients, which were chosen to modulate keratin levels in EB patients in anticipation of having a disease-modulating effect. A secondary reason for selecting these cannabinoids was to address EB symptoms, including inflammation, wound healing, skin regeneration, itching and pain. In development as a topical application, INM-750 is designed to optimize penetration of the cannabinoids to the skin’s epidermal/dermal junction.

Through the agreement with Pharmaseed, which is the largest GLP-certified preclinical contract research organization in Israel, InMed is taking another step toward moving INM-750 to its first clinical trial. Under the terms of the agreement, Pharmaseed will develop a final formulation for INM-750 for ongoing R&D, including IND-enabling pharmacology and toxicology studies and eventual clinical studies. The contract also includes the development of assay methods for manufacturing, stability, quality assurance and other methods of analysis.

A preclinical-stage biopharmaceutical company, InMed specializes in the research and development of cannabinoid-based prescription drug therapies that utilize novel drug delivery systems. For its product candidates, the company conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities. InMed’s primary value drivers are its proprietary bioinformatics database assessment tool, biosynthesis manufacturing process and drug development programs.

For more information, visit the company’s website at

About NetworkNewsWire

NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s